Non-Small Cell Lung Cancer News

Latest Non-Small Cell Lung Cancer News

Sun, 01 Nov 2009 14:52:03 +0100

Latest news for Non-Small Cell Lung Cancer updated every 30 minutes, dedicated for patients, caregivers, physicians and researchers whose interest are non-small cell lung cancer, nsclc, lung cancer treatment.

How to Quit Smoking - The Quit Smoking Company

Sun, 01 Nov 2009 14:52:03 +0100

Information and Products to Help Smokers Quit. Youll learn how to set a quit date, quit, and avoid weight gain. Learn ways to make quitting easier, even if you are a long-time smoker. Take a look at our quitting articles and stop smoking today. Read more ...

Drug-Radiation Combo Used To Eradicate Lung Cancer In Mouse Model

Sat, 31 Oct 2009 10:17:16 +0100

Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

Drug-Radiation Combo Used To Eradicate Lung Cancer

Fri, 30 Oct 2009 14:16:13 +0100

Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.In a study appearing in the October issue of Cancer Research, UT Southwestern researchers found that if they administered BEZ235 before they damaged the DNA of tumor cells with otherwise nontoxic radiation, the ...

Drug-radiation Combo Eradicates Lung Cancer In Mice

Thu, 29 Oct 2009 15:18:31 +0100

Researchers have eliminated non-small cell lung cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

Intervals between lung cancer diagnosis and treatment displays a health care disparity

Sun, 01 Nov 2009 03:33:01 +0100

( International Association for the Study of Lung Cancer ) Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies.

Celera Licenses Protein IP for Lung Cancer Dx

Fri, 30 Oct 2009 13:35:08 +0100

NEW YORK (GenomeWeb News)Celera said today that it has licensed the rights to use Medical Therapies Limited's patent portfolio for the protein midkine in its lung cancer diagnostics programs.

Novel therapy may eradicate lung cancer

Fri, 30 Oct 2009 08:05:59 +0100

Washington, Oct 30 : Scientists from UT Southwestern Medical Center have suggested a novel therapeutic strategy that would completely eradicate lung cancer.

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics (News-Medical-Net)

Fri, 30 Oct 2009 03:30:44 +0100

Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY?s midkine patent portfolio for the development of novel lung cancer diagnostics.

November Is Lung Cancer Month: Know The Latest Information About This Deadliest Of Cancers

Thu, 29 Oct 2009 12:17:06 +0100

Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year.(1) It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.

One of World's Deadliest Cancers Eliminated from Lungs of Mice by New Drug, Radiation

Thu, 29 Oct 2009 19:58:57 +0100

Oct. 29, 2009One of the most dangerous of cancersnon-small cell lung (NSCL) cancerhas been totally eliminated from laboratory mice at UT Southwestern Medical Center by the use of an investigative drug called BEZ235 in combination with low-dose radiation.

Lung Cancer Ribbon

Sun, 01 Nov 2009 14:52:03 +0100

Lung Cancer Support Ribbon Lapel Pins. - Made in U.S.A. - Help Increase Lung Tumor Awareness and Early Detection.

Metastatic non-small-cell lung cancers overexpress the SKP2 gene.

2004 AUG 24 - - Metastatic non-small-cell lung cancers overexpress the SKP2 gene. According to a study from Japan, "SKP2, an F-box protein constituting the substrate recognition subunit of the SCFSKP2 ubiquitin ligase complex, is implicated in ubiquitin-mediated ...

COX-2 and tumor angiogenesis correlate in non-small cell lung cancers.

2003 DEC 16 - - COX-2 and tumor angiogenesis correlate in non-small cell lung cancers. "The role of cyclooxygenase -2 expression and angiogenesis of lung cancer is yet to be delineated. Eighty four non-small cell lung cancer specimens were evaluated for ...

HER-2, EGFR, and COX-2 are overexpressed in some non-small cell lung cancers.

2004 MAR 30 - - HER-2, EGFR, and COX-2 are overexpressed in some non-small cell lung cancers. According to recent research published in the journal Acta Oncologica, "the incidence of lung cancer is increasing throughout the world and is the most common cause of ...

N-terminal deletion augments BAX activity in non-small cell lung cancers.

2003 JUN 23 - - N-terminal deletion augments BAX activity in non-small cell lung cancers. According to recent research from Japan, "therapeutic modalities that overcome the antiapoptotic function of Bcl-2 that is often overexpressed in cancer cells are expected to be ...

Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPROXYN Exposure in Patients with Brain Metastases from Breast and Non-Small Cell Lung Cancers.

WESTMINSTER, Colo., June 14 /PRNewswire-FirstCall/ - Allos Therapeutics, Inc. today announced the publication of new findings from its Phase 3 REACH study of EFAPROXYN plus whole brain radiation therapy in patients with brain metastases from various primary cancers. Results of the ...

ImmunoGen Reports Results from Phase I/II Human Clinical Study with Product Candidate for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers.

-Data Reported at the 2001 Annual Meeting of American Society of Clinical Oncology- CAMBRIDGE, Mass., May 13 /PRNewswire/ - ImmunoGen, Inc. today announced safety and pharmacokinetic data from 37 patients enrolled in the first human clinical trial of its Tumor-Activated Prodrug ...

ImmunoGen Reports Promising Results from Phase I/II Human Clinical Study with Product Candidate for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers.

-Data Reported at the 2001 Annual Meeting of American Society of Clinical Oncology- CAMBRIDGE, Mass., May 14 /PRNewswire/ - ImmunoGen, Inc. today announced safety and pharmacokinetic data from 37 patients enrolled in the first human clinical trial of its Tumor-Activated Prodrug ...

ImmunoGen Begins Enrollment in a Third Phase I/II Human Clinical Study with Lead Product for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers.

Clinical Trial Designed to Study Safety of Compound in a More Dose-Intensive Regimen; Clinical Development Program Continues on Track CAMBRIDGE, Mass., May 8 /PRNewswire/ - ImmunoGen, Inc. today announced that it has begun enrollment for a third Phase I/II human clinical study with ...

Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report.

M2 PRESSWIRE-5 May 2009-Research and Markets: Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report1994-2009 M2 COMMUNICATIONS LTD RDATE:05052009 Dublin - Research and Markets (httpwww.researchandmarkets.com/research/8642d7/nonsmallcell_lun) has ...

Hycamtin Achieves Promising Results in Patients With Non-Small Cell Lung Cancer

DENVER, May 19 /PRNewswire/ - According to a study presented today at the 33rd annual meeting of the American Society of Clinical Oncology , Hycamtin (topotecan hydrochloride for injection, SmithKline Beecham may offer a promising new treatment option for patients suffering ...

Asbestos Home Test Kit

Sun, 01 Nov 2009 14:52:03 +0100

Asbestos is a health hazard in many homes, offices and schools. - Asbestos exposure can cause lung cancer. - Order an easy to use Home Test right now!